Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma

Summary

Monitoring of anti-factor Xa activity is often performed during treatment with low-molecular-weight heparins (LMWHs) in pregnancy because the anticoagulant effect may decrease as pregnancy progresses, but assays for anti-factor Xa activity are unavailable in many clinical institutions caring for pregnant women. Heptest-STAT is a new clotting assay for monitoring of LMWHs, which has been optimised for use in near-patient laboratory instrumentation. It has been suggested that monitoring of LMWHs requires the use of individual calibration curves for each LMWH.We compared the dose response of four conventional LMWHs and fondaparinux in normal plasma, and plasma from women in first, second and third trimester of pregnancy. Three concentrations of LMWHs, fondaparinux, or unfractionated heparin were added to pooled plasma samples from nonpregnant women (n=10), and pregnant women in first (n=10), second (n=10) and third (n=10) trimester of pregnancy. Heptest results are not influenced by the stage of pregnancy. In contrast, dose-related aPTT prolongation declines during pregnancy. All LMWHs tested, as well as fondaparinux, display a similar doseresponse in Heptest compared to the chromogenic anti-factor Xa assay. Heptest-STAT can be used with the same standard calibration for non-pregnant and pregnant patients and for all LMWHs under investigation, including fondparinux. No individual calibrations are necessary.

Keywords

Heparins - LMWH - pregnancy - heptest - fondaparinux - monitoring

• References

• 1 Deruelle P, Coulon C. The use of low-molecularweight heparins in pregnancy--how safe are they?. Curr Opin Obstet Gynecol 2007; 19: 573-577.
• 2 McColl MD, Greer IA. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy. Curr Opin Pulm Med 2004; 10: 371-375.
• 3 Hills FA, Abrahams VM, Gonzalez-Timon B. et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod 2006; 12: 237-243.
• 4 Ganapathy R, Whitley GS, Cartwright JE. et al. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 2007; 22: 2523-2527.
• 5 Kawamata K, Neki R, Yamanaka K. et al. Risks and pregnancy outcome in women with prosthetic mechanical heart valve replacement. Circ J 2007; 71: 211-213.
• 6 Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004; 92: 747-751.
• 7 Casele HL. The use of unfractionated heparin and low molecular weight heparins in pregnancy. Clin Obstet Gynecol 2006; 49: 895-905.
• 8 Campbell PJ, Tirvengadum MA, Pickering W. et al. HEPTEST: a suitable method for monitoring heparin during pregnancy. Clin Lab Haematol 1999; 21: 193-199.
• 9 Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
• 10 Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973; 81: 298-310.
• 11 Yin ET, Denson KW. Letter: Procedure for the determination of heparin. Thromb Diath Haemorrh 1975; 33: 393-395.
• 12 Kitchen S, Iampietro R, Woolley AM. et al. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-1293.
• 13 Abbate R, Gori AM, Farsi A. et al. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998; 82: 33L-36L.
• 14 Bara L, Combe-Tamzali S, Conard J. et al. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest). Haemostasis 1987; 17: 127-133.
• 15 Harenberg J. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins. J Mal Vasc 1987; 12 (Suppl B) 68-70.
• 16 Abildgaard U, Norrheim L, Larsen AE. et al. Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay. Haemostasis 1990; 20: 193-203.
• 17 Bara L, Mardiguian J, Samama M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990; 57: 585-592.
• 18 Walenga JM, Hoppensteadt D, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res (Suppl) 1991; 14: 49-62.
• 19 Chunilal SD, Young E, Johnston MA. et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002; 87: 92-97.
• 20 Abou-Nassar K, Kovacs MJ, Kahn SR. et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia A randomized trial. Thromb Haemost 2007; 98: 163-171.
• 21 Norris LA, Bonnar J, Smith MP. et al. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy A pharmacokinetic study. Thromb Haemost 2004; 92: 791-796.
• 22 Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 627S-644S.
• 23 Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004; 148: 582-589.
• 24 Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001; 12: 229-236.
• 25 Alesci S, Borggrefe M, Dempfle CE. Effect of freezing method and storage at -20 degrees C and -70 degrees C on prothrombin time, aPTT and plasma fibrinogen levels. Thromb Res 2009; 124: 121-126.
• 26 Akerblom O, Bremme K, Dackland AL. et al. Freezing technique and quality of fresh-frozen plasma. Infusionsther Transfusionsmed 1992; 19: 283-287.